Xencor (NASDAQ:XNCR) Reaches New 52-Week Low at $16.00

Xencor, Inc. (NASDAQ:XNCR)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $16.00 and last traded at $16.08, with a volume of 565162 shares. The stock had previously closed at $17.85.

Analysts Set New Price Targets

Several research analysts have recently weighed in on XNCR shares. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price target on shares of Xencor in a research note on Tuesday. Wedbush reissued an “outperform” rating and issued a $34.00 target price (down previously from $36.00) on shares of Xencor in a research report on Thursday, June 13th. BTIG Research reduced their price target on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, April 16th. BMO Capital Markets restated an “outperform” rating and set a $32.00 price objective on shares of Xencor in a research report on Tuesday. Finally, Raymond James decreased their target price on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research note on Friday, June 14th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.44.

Xencor Stock Down 11.6 %

The company has a quick ratio of 7.08, a current ratio of 7.08 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $20.25 and a 200-day simple moving average of $21.24. The firm has a market cap of $972.99 million, a P/E ratio of -7.55 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). Xencor had a negative net margin of 82.23% and a negative return on equity of 20.29%. The company had revenue of $16.96 million for the quarter, compared to the consensus estimate of $21.13 million. During the same quarter last year, the firm posted ($0.37) earnings per share. The company’s revenue was down 62.7% compared to the same quarter last year. On average, equities analysts anticipate that Xencor, Inc. will post -3.56 earnings per share for the current year.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 36,329 shares of the company’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $18.32, for a total value of $665,547.28. Following the completion of the transaction, the vice president now owns 192,319 shares of the company’s stock, valued at $3,523,284.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in XNCR. Parallel Advisors LLC grew its holdings in Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,015 shares in the last quarter. CWM LLC increased its holdings in shares of Xencor by 498.7% in the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,147 shares during the last quarter. Signaturefd LLC raised its position in shares of Xencor by 367.7% during the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,151 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Xencor by 153.7% in the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,316 shares during the last quarter. Finally, Allworth Financial LP grew its position in Xencor by 29,487.5% in the fourth quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 2,359 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.